Month: March 2026

Release – Perfect’s Board Announces the Formation of Special Committee to Evaluate on the Preliminary Non-Binding “Going Private” Proposal Received on March 18, 2026

Posted on by [email protected]

Research News and Market Data on PERF

March 23, 2026

NEW YORK–(BUSINESS WIRE)– Perfect Corp. (NYSE: PERF) (“Perfect” or the “Company”), a leading artificial intelligence (“AI”) company offering AI and augmented reality (“AR”) powered solutions to beauty, fashion, photo and video creative industries, today announced that its board of directors (the “Board”) has formed a special committee (the “Special Committee”) consisting of three disinterested, independent directors, namely Philip Tsao, who will serve as the chairman of the Special Committee, Chung-Hui (Christine) Jih and Meng-Shiou (Frank) Lee, to evaluate and consider the preliminary non-binding proposal letter, received on March 18, 2026 (the “Proposal”) from the consortium formed by CyberLink International Technology Corp. (“CyberLink”) and Ms. Alice H. Chang, Chairwoman of the Board and Chief Executive Officer of Perfect and her controlled entities, that proposes a “going-private” transaction for US$1.95 per ordinary share in cash (the “Transaction”).

The Special Committee is authorized to retain advisors, including independent legal and financial advisors, to assist it in its work.

The Company cautions its shareholders and others considering trading in its securities that neither the Board nor the Special Committee has made any decision with respect to the Company’s response to the Proposal. There can be no assurance that any definitive offer will be received, that any definitive agreement will be executed relating to the Transaction, or that the Transaction or any other similar transaction will be approved or consummated. The Company does not undertake any obligation to provide any updates with respect to any transaction, except as required under applicable law.

About Perfect Corp.

Founded in 2015, Perfect Corp. is a leading AI company offering self-developed AI- and AR-powered solutions dedicated to transforming the world with digital tech innovations that make your virtual world beautiful. On Perfect’s direct consumer business side, Perfect operates a family of YouCam consumer apps and web-editing services for photo, video and camera users, centered on unleashing creativity with AI-driven features for creation, beautification and enhancement. On Perfect’s enterprise business side, Perfect empowers major beauty, skincare, fashion, jewelry, and watch brands and retailers by supplying them with omnichannel shopping experiences through AR product try-ons and AI-powered skin diagnostics. With cutting-edge technologies such as Generative AI, real-time facial and hand 3D AR rendering and cloud solutions, Perfect enables a personalized, enjoyable, and engaging shopping journey and helps brands elevate customer engagement, increase conversion rates, and propel sales growth. Throughout this journey, Perfect maintains its unwavering commitment to environmental sustainability and fulfilling social responsibilities. For more information, visit https://ir.perfectcorp.com/.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, or the Exchange Act, that are based on beliefs and assumptions and on information currently available to Perfect. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” “target,” “seek” or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Any statements that refer to expectations, projections or other characterizations of future events or circumstances, including strategies or plans, are also forward-looking statements. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. These statements are based on Perfect’s reasonable expectations and beliefs concerning future events and involve risks and uncertainties that may cause actual results to differ materially from current expectations. These factors are difficult to predict accurately and may be beyond Perfect’s control. Forward-looking statements in this communication or elsewhere speak only as of the date made. New uncertainties and risks arise from time to time, and it is impossible for Perfect to predict these events or how they may affect Perfect. In addition, risks and uncertainties are described in Perfect’s filings with the Securities and Exchange Commission. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Perfect cannot assure you that the forward-looking statements in this communication will prove to be accurate. There may be additional risks that Perfect presently does not know or that Perfect currently does not believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by Perfect, its directors, officers or employees or any other person that Perfect will achieve its objectives and plans in any specified time frame, or at all. Except as required by applicable law, Perfect does not have any duty to, and does not intend to, update or revise the forward-looking statements in this communication or elsewhere after the date of this communication. You should, therefore, not rely on these forward-looking statements as representing the views of Perfect as of any date subsequent to the date of this communication.

Investor Relations Contact
Investor Relations, Perfect Corp.
Email: [email protected]

Source: Perfect Corp.

Banzai’s Bold Bet: Microcap MarTech Player Eyes Revenue-Doubling Acquisition of ConnectAndSell

Posted on by [email protected]

Banzai International (Nasdaq: BNZI) just made a move that could fundamentally reshape what the microcap marketing technology company looks like by summer — and the numbers tell a striking story.

The Austin-based AI marketing platform announced late last week that it has reached terms to acquire the assets of ConnectAndSell, an AI-powered sales acceleration platform serving B2B organizations across healthcare, financial services, and technology. The deal, structured around a non-binding letter of intent, is expected to close in early Q2 2026, pending a definitive agreement and customary closing conditions.

The strategic rationale is straightforward on paper: Banzai recorded approximately $10.65 million in revenue over the trailing twelve months ending Q3 2025. The ConnectAndSell acquisition is projected to add roughly $15 million in annual revenue — meaning the deal alone would more than double the company’s current revenue run rate if integration goes according to plan. For a company with a market cap hovering around $14 million, that kind of top-line expansion isn’t incremental — it’s transformational.

ConnectAndSell is not a startup. It is an established, profitable business with a track record of generating real revenue across enterprise and mid-market accounts. Its platform is designed to dramatically increase sales team productivity by maximizing time spent in live conversations with qualified decision-makers — a capability that sits at the highest-value stage of the go-to-market funnel. For Banzai, which already helps companies target, engage, and measure marketing outcomes, layering in sales execution capabilities creates an end-to-end revenue platform that few companies at this market cap can claim.

The deal follows Banzai’s acquisition of Superblocks in November 2025, an agentic AI platform for SEO-optimized website development. The pattern is becoming clear: Banzai is pursuing a deliberate build-out strategy, acquiring profitable, AI-native tools that are immediately accretive and strategically complementary rather than chasing speculative moonshots.

Cross-sell opportunity is a core part of the investment thesis here. Banzai’s existing customer base includes more than 140,000 organizations — among them RBC, Dell Technologies, New York Life, and Thermo Fisher Scientific. Introducing ConnectAndSell’s sales acceleration capability to even a fraction of that base could generate meaningful incremental revenue beyond the $15 million headline figure.

Still, investors should keep a few realities in check. The transaction remains at the letter of intent stage — no definitive agreement has been signed, and no purchase price has been disclosed, creating near-term financial transparency uncertainty. Banzai’s stock has also declined roughly 89% over the past year, sitting just below the $1 mark, which reflects a company that has been fighting uphill on the balance sheet even as it executes strategically. Management is scheduled to discuss the proposed acquisition in detail on a conference call March 31, 2026 at 4:30 p.m. Eastern Time, which will be the next critical data point for investors watching this deal develop.

For small and microcap investors, Banzai’s acquisition playbook is worth watching. In a market where platform consolidation is increasingly the path to survival and scale, companies that can string together profitable, AI-powered assets at reasonable valuations may be positioning themselves for an outsized rerating when the market conditions turn. Whether BNZI can execute on that vision is the question the rest of 2026 will answer.

GDEV (GDEV) – Improved Profitability Appears Sustainable

Posted on by [email protected]


Tuesday, March 24, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Solid Q4 results. The company reported Q4 revenue of $90.0 million and adj. EBITDA of $15.0 million. While revenue was modestly below our estimate of $99.0 million, adj. EBITDA was in line with our estimate of $15.1 million. Notably, the strong adj. EBITDA figure was largely driven by more efficient use of marketing spend, which decreased approximately 25% compared to the prior year period.

Key operating metrics. Bookings and monthly paying users (MPU) decreased by 7% and 10%, respectively, compared with the prior year period, but the decrease was expected as the company is focused on the quality of gameplay and retaining high-quality users. Furthermore, the company’s strategy appears to be paying off, as average bookings per paying user (ABPPU) increased from $102 in Q4’24 to $106 in Q4’25.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Trump Pays a French Energy Giant to Exit U.S. Offshore Wind — and Redirects the Money to Fossil Fuels

Posted on by [email protected]

The Trump administration has agreed to refund $1 billion in offshore wind lease fees to French energy giant TotalEnergies, effectively paying the company to abandon two major U.S. wind projects and redirect that capital into oil, gas, and liquefied natural gas development. The move marks one of the most aggressive — and costly — steps yet in the administration’s campaign to dismantle the offshore wind industry built up under the Biden era.

The Department of Interior announced Monday that TotalEnergies will surrender its leases for planned offshore wind projects off the coasts of North Carolina and New York. In exchange, the company will receive reimbursement up to the full amount it paid to acquire those leases. TotalEnergies has also pledged not to pursue any new offshore wind development in the United States. The refunded capital will be redirected toward the construction of a liquefied natural gas facility in Texas and the expansion of the company’s broader U.S. oil and gas portfolio.

For context, TotalEnergies paid roughly $133,000 for the North Carolina lease and approximately $795,000 for the New York and New Jersey lease — both purchased in 2022 during the height of the Biden administration’s offshore wind push. The Carolina Long Bay project had been designed to generate over one gigawatt of power, enough to supply roughly 300,000 homes. The New York project was even larger, with a planned capacity of three gigawatts capable of powering close to one million homes.

The deal raises immediate questions about the use of public funds. Environmental advocates were quick to characterize it as taxpayer money being spent to eliminate clean energy capacity rather than build it — particularly at a moment when the Iran conflict has sent oil prices surging and renewed global debate about energy security and diversification.

This transaction also comes after the administration’s earlier attempts to halt offshore wind construction were struck down by federal courts. Judges overturned executive orders that had targeted five major East Coast wind projects on national security grounds, allowing construction to continue. The TotalEnergies deal appears to signal a strategic pivot — using financial settlements to achieve what legal orders could not.

The broader energy policy picture is shifting rapidly. Ironically, on the same day this deal was announced, one of the offshore wind farms previously targeted by the administration — Coastal Virginia Offshore Wind — began delivering power to the Virginia grid. The developer, Dominion Energy, confirmed the milestone, underscoring the fact that the offshore wind industry, despite significant political headwinds, continues to advance.

For investors in the small and microcap energy space, the implications cut both ways. Companies with exposure to LNG infrastructure, domestic oil and gas development, and fossil fuel supply chains stand to benefit from the administration’s policy direction and capital reallocation. On the other side, smaller renewable energy developers and wind supply chain companies face an increasingly hostile regulatory and financial environment in the U.S., even as offshore wind capacity expands globally — with China leading the world in new installations.

The $1 billion question is whether this deal represents a one-time settlement or the beginning of a broader pattern of government-funded exits from the U.S. renewable energy sector.

Release – Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026

Posted on by [email protected]

Research News and Market Data on TNXP

March 23, 2026 4:32pm EDTDownload as PDF

Monday, March 30: Phase 1 data on TNX-4800 (long-acting anti-Borrelia OspA human monoclonal antibody) for the seasonal prevention of Lyme disease 

Wednesday, April 1: Animal and in vitro studies on TNX-801 (horsepox, live virus vaccine) for the prevention of smallpox and mpox

Wednesday, April 1: Horsepox as a modular antigen-delivery system for broad and sustained immunity in novel vaccines to protect against other pathogens

BERKELEY HEIGHTS, N.J., March 23, 2026 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, today announced an oral presentation of Phase 1 data on TNX-4800 (formerly known as mAb 2217LS)1,2, a long-acting human monoclonal antibody (mAb) that targets the outer surface protein A (OspA) of Borrelia burgdorferi, the causative agent of Lyme disease in humans in the U.S., at the World Vaccine Congress Washington 2026 held in Washington, D.C., March 30-April 2, 2026.

The Company’s Farooq Nasar, PhD, Director, Virology will present data on TNX-801, the Company’s attenuated, live orthopoxvirus (horsepox) vaccine candidate with the potential capability to protect against smallpox and mpox. Finally, Christopher Cooper, PhD, Director, Immunology at Tonix will serve as moderator on a panel discussing modular antigen-delivery systems in novel pox-based vaccines.

TNX-4800 Presentation Details

Title: A Long-Acting Monoclonal Antibody for Seasonal Prevention of Lyme Disease
Location: Room 202B
Date and Time: March 30, 2026, 10:10 a.m. ET
Session Category: Measuring Breadth & Emerging Targets
Presenters: Mark S. Klempner, MD, Professor of Medicine at UMass Chan Medical School, inventor of TNX-4800, and Principal Investigator of the study

Other Session Details

Title: A Live Attenuated, Minimally Replicative MPOX Vaccine
Location: Room 202A, Level 2
Date and Time: April 1, 2026, 10:10 am ET
Session Category: Emerging & Re-Emerging Diseases
Presenter: Farooq Nasar, PhD, Director, Virology, Research and Development Center (RDC), Tonix Pharmaceuticals

Title: Poxvirus as a Modular Antigen-Delivery System for Broad and Sustained Immunity
Location: Room 20A, Level 2
Date and Time: April 1, 2026, 3:25 p.m. ET
Session Category: Emerging & Re-Emerging Diseases
Moderator: Christopher Cooper, PhD, Director, Immunology, RDC, Tonix Pharmaceuticals

About TNX-4800
TNX-4800 (formerly known as mAb 2217LS) is a human monoclonal antibody with an engineered extended half-life that targets the outer-surface protein A (OspA) on Lyme-causing Borrelia bacteria. When TNX-4800-containing blood is ingested by the tick, TNX-4800 kills and blocks the maturation of Borrelia burgdorferi in the mid-gut of infected deer ticks. The Company in-licensed TNX-4800 from UMass Chan Medical School in 2025. Published work in animals showed that TNX-4800 was 95% effective in preventing infection after a six-day challenge with ticks infected with Borrelia burgdorferi.1 TNX-4800 was derived from mAb 2217 by amino acid substitutions in its crystallizable fragment (Fc) domain which serve to prolong the serum half-life. A single administration in the Spring is designed to potentially provide immunity within two days and maintain protective antibody titers for the entire tick season, providing pre-exposure prophylaxis against Lyme disease without relying on the recipient’s immune system to generate antibodies. By delivering a well-characterized antibody directly, TNX-4800 has been shown to block transmission of Borrelia burgdorferi from ticks to animals. TNX-4800 also sidesteps the multidose schedules required for OspA vaccines in development3 and the FDA-approved vaccine that was withdrawn from the market.4 The Company expects to have GMP investigational product available for clinical testing in early 2027. Pending FDA clearances, a field study is expected to initiate enrollment in the first half of 2027, and a controlled human infection model (CHIM) study in 2028.

About the TNX-4800 Phase 1 Study
TNX-4800 was studied in a randomized, double-blind, sequential dose-escalation study (NCT04863287) that evaluated safety, tolerability, pharmacokinetics (PK), and immunogenicity of TNX-4800 in healthy adults. 44 subjects were randomized, and 41 completed the study. Subjects received a single subcutaneous (SC) administration of placebo or TNX-4800 at 0.5, 1.5, 5, or 10 mg/kg. Safety was assessed via clinical and lab evaluations. Drug exposure increased by approximately 25 times for a 20 times increase in dose. Serum TNX-4800 was measurable at the earliest sampling time of 24 hours, indicating rapid systemic absorption. TNX-4800 concentrations remained quantifiable for >200 days in 80% of volunteers at the lowest dose and for up to 350 days in the majority of volunteers at higher doses (i.e., ≥ 1.5 mg/kg). Mean half-life ranged from 62-69 days across groups. Serum concentrations remained quantifiable for up to 12 months in most subjects. Mean exposure for the 10 mg/kg cohort was less than 20% of the highest exposures in a rat toxicology study. Anti-drug antibodies (ADA) were detected in <10% of treated subjects, with no impact on PK. Most adverse events were mild or moderate. TNX-4800 was determined to be generally safe and well tolerated.

About Lyme Disease 
In the United States, Lyme disease is caused by the bacterium Borrelia burgdorferi. Lyme disease remains the most common vector-borne infection in the United States, and its incidence is climbing each year, due in part to global changes in climate expanding the habitat range for ticks.5 It occurs most commonly in the Northeast, mid-Atlantic, and upper-Midwest regions. Lyme disease bacteria are transmitted through the bite of infected Ixodes ticks. Typical symptoms include fever, headache, fatigue, and a characteristic skin rash called erythema migrans. If left untreated, infection can spread to joints, heart, and nervous system. Laboratory testing is helpful if used correctly and performed with FDA-cleared tests. Although many cases of Lyme disease can be treated successfully with antibiotics, diagnosis and treatment are often delayed or missed. Chronic Lyme is considered an Infection Associated Chronic Illness (IACI), and is a chronic, debilitating disease state characterized by joint and muscle pain, fatigue, and other symptoms.6

About TNX-801
TNX-801 (recombinant horsepox virus) is an attenuated, minimally replicative, live virus vaccine based on horsepox in pre-clinical development to prevent mpox and smallpox. TNX-801 is expected to enter a Phase 1 study in 2027 pending FDA clearance. TNX-801 is in the pre-IND stages of development.

Citations
1Schiller ZA, et al. J Clin Invest. 2021 131(11):e144843.
2Wang Y, et al. J Infect Dis. 2016. 214(2):205-11.
3Comstedt P, et al. Vaccine. 2015 33(44):5982-8.
4Connaught’s (ImuLyme™) and SmithKline Beecham’s (LYMErix™) Lyme disease vaccines were withdrawn. Nigrovic LE, et al. Epidemiol Infect. 2007 135(1):1-8. doi: 10.1017/S0950268806007096. Epub 2006 Aug 8. PMID: 16893489; PMCID: PMC2870557.
5Gomes-Solecki M, et. al. Clin Infect Dis. 2020 70(8):1768-1773. doi: 10.1093/cid/ciz872. PMID: 31620776; PMCID: PMC7155782.
6National Academies of Sciences, Engineering, and Medicine. 2025. Charting a Path Toward New Treatments for Lyme Infection-Associated Chronic Illnesses. Washington, DC: The National Academies Press. https://doi.org/10.17226/28578.

Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals* is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg), is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. In addition, the Company’s CNS portfolio includes TNX-2900 (intranasal oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including long-acting human monoclonal antibody TNX-4800 for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X.

*Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 including those relating to the completion of the offering, the satisfaction of customary closing conditions, the intended use of proceeds from the offering and other statements that are predictive in nature. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially as a result of a number of factors, including the ability of the Company to satisfy the conditions to the closing of the offering and the timing thereof, as well as those described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 12, 2026, and periodic reports filed with the SEC on or after the date thereof. Tonix does not undertake an obligation to update or revise any forward-looking statement. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contacts
Jessica Morris
Tonix Pharmaceuticals
[email protected]
(862) 799-8599

Brian Korb
astr partners
(917) 653-5122
[email protected]

Media Contacts
Deborah Elson
Tonix Pharmaceuticals 
[email protected]

Ray Jordan
Putnam Insights
[email protected]

Primary Logo

Source: Tonix Pharmaceuticals Holding Corp.

Released March 23, 2026

Release – Newsmax Appoints David Evans to Board of Directors

Posted on by [email protected]

Research News and Market Data on NMAX

March 23, 2026

Former CFO and COO Brings 25 Years of Public Company Financial and Operational Leadership

Evans Adds Digital Media Expertise to Newsmax Board as Company Expands Streaming Services
and Audience Reach

BOCA RATON, FL / ACCESS Newswire / March 23, 2026 / Newsmax Inc. (NYSE:NMAX) (“Newsmax” or the “Company”) today announced the appointment of David Evans to the Company’s Board of Directors, effective on Thursday, March 19th. Evans brings extensive public company financial leadership and digital media expertise to Newsmax as the Company continues to expand as one of America’s leading news networks.

“We are thrilled to welcome David Evans to the Newsmax Board of Directors,” said Christopher Ruddy, CEO of Newsmax. “David’s exceptional track record as a CFO and COO of a publicly traded multi-media company, combined with his deep expertise in both digital media transformation and the capital markets, makes him an invaluable addition to our Board. His professional background, specifically his deep experience scaling digital businesses, aligns perfectly with Newsmax’s strategic priorities as we continue to grow our streaming services and expand our overall reach.”

Evans joins the six existing members of the Newsmax Board of Directors including CEO Christopher Ruddy, U.S. Secretary of Labor Alex Acosta, Ambassador Nancy Brinker, Chris Nixon Cox, Ambassador Paula Dobriansky and David Gandler.

David Evans

David Evans is a board-ready executive and audit committee financial expert with 25 years of progressive leadership at a publicly listed multi-media company, including roles as Chief Financial Officer, Chief Operating Officer and Division President of New Media and Publishing. He combines deep expertise in financial oversight, SEC reporting and corporate governance with hands-on experience scaling digital media businesses across streaming, OTT TV, podcasting, e-commerce, digital advertising and social media.

Most recently serving as Chief Operating Officer of Salem Media Group from 2022 to 2025, Evans directed all operations with specific oversight of the digital media, e-commerce and finance functions. He previously served as Division President of New Media & Publishing from 2007 to 2021.

As Executive Vice President and Chief Financial Officer from 2000 to 2006, he instituted the company’s SOX compliance framework, helped triple the company’s stock price, executed a $93 million equity offering at a then record EBITDA multiple for the radio broadcast industry and secured more than $500 million in debt capital at industry-leading terms while guiding the company’s strategic pivot to digital media. Earlier, Evans held senior leadership positions at Warner Bros. Consumer Products, including Senior Vice President and Managing Director for Europe, Middle East and Africa.

Evans is a Chartered Accountants of England and Wales, where he achieved 5th place national ranking. He earned a Bachelor of Science (Honors) in Managerial and Administrative Studies with a specialization in Finance, Accounting and Strategic Planning from the University of Aston in Birmingham, England.

About Newsmax

Newsmax Inc. is listed on the NYSE (NMAX) and operates, through Newsmax Broadcasting LLC, one of the nation’s leading news outlets, the Newsmax channel. The fourth highest-rated network is carried on all major pay TV providers. Newsmax’s media properties reach more than 50 million Americans regularly through Newsmax TV, the N2 Channel, the Newsmax App, its popular website Newsmax.com, and publications such as Newsmax Magazine. Through its social media accounts, Newsmax reaches over 22 million combined followers. Reuters Institute says Newsmax is one of the top U.S. news brands and Forbes has called Newsmax “a news powerhouse.”

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning Newsmax’s strategic priorities, growth plans, streaming expansion, audience reach, digital initiatives, and the anticipated contributions of David Evans as a member of the Company’s Board of Directors. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements. Factors that could cause actual results to differ materially include, among others, changes in market, business, economic, competitive, technological, regulatory and other conditions, as well as the risks described from time to time in the Company’s periodic filings with the Securities and Exchange Commission. Newsmax undertakes no obligation to update any forward-looking statements, except as required by law.

For more information, please visit Investor Relations | Newsmax Inc.

Investor Contacts
Newsmax Investor Relations
[email protected]

SOURCE: Newsmax Inc.

View the original press release on ACCESS Newswire

Small Caps Surge 3% as Iran Talks Spark One of the Market’s Best Single-Day Reversals

Posted on by [email protected]

The small-cap market opened Monday in the crosshairs of a global selloff, only to stage one of its most dramatic single-session recoveries in recent memory — all within the span of a few hours. The whipsaw move underscores just how vulnerable smaller, domestic-focused companies have become to the escalating conflict in the Middle East, and how quickly sentiment can shift on a presidential comment.

Going into this week, the Russell 2000 — the primary benchmark for small-cap equities — had already shed more than 7% in March alone, entering official correction territory last Friday with a decline exceeding 10% from its recent peak. The index, which had started the year as a market leader riding optimism around rate cuts and a rotation away from mega-cap tech, has now given back virtually all of those gains. As of last Thursday, the index’s year-to-date return had collapsed to less than 1%.

The catalyst for the unraveling has been the ongoing U.S.-Israel conflict with Iran. Since military operations began, Brent crude futures surged more than 40%, briefly touching $119 per barrel before pulling back. The ripple effects have been severe for small caps specifically. Unlike large-cap multinationals with diversified revenue streams and investment-grade credit, smaller companies are more exposed to rising input costs, tighter credit markets, and slowing consumer demand — the exact cocktail that an oil shock delivers.

The pain goes deeper than sentiment. Analysts now estimate that between 41% and 46% of Russell 2000 companies are unable to cover their interest expenses with operating income. These so-called zombie companies face a $368 billion debt maturity wall in 2026, and with the 10-year Treasury yield spiking to 4.38% by Friday — up sharply from the mid-3% range at the start of the year — refinancing that debt is significantly more expensive. The Federal Reserve’s decision to hold rates steady at 3.50%–3.75% at its March 18th meeting, while revising its inflation outlook upward, effectively removed any near-term cushion the market was counting on.

Then came Monday’s reversal.

Overnight, global markets were in freefall. South Korea’s KOSPI dropped over 6%, Japan’s Nikkei fell more than 3%, and European equities opened deep in the red. U.S. futures pointed to a fifth consecutive down week for American stocks. But within the first hour of trading, the picture changed completely. President Trump signaled he was postponing threatened strikes on Iranian power infrastructure, citing productive negotiations. Brent crude fell more than 10% on the news. U.S. equities surged, with the Russell 2000 climbing more than 3% intraday — one of the index’s strongest single-day moves of the year — reclaiming the 2,500 level.

For small-cap investors, this session captures exactly what makes the asset class both compelling and treacherous. Bank of America has noted that while the Russell 2000 tends to sell off more sharply than large caps in risk-off environments, it also tends to recover faster — historically outpacing large caps by more than a percentage point within three months of a geopolitical shock.

The Iran situation is far from resolved. But today’s action is a reminder that in small caps, the most dangerous moments often precede the most significant opportunities.

Release – SKYX Announces Corporate Update Call

Posted on by [email protected]

Research News and Market Data on SKYX

Company to Provide Corporate Updates including New Developments, Fourth Quarter 2025 and 2025 Full Year Overview and Financial Results; Conference Call to be Held on Thursday March 26, 2026, at 4:30 PM Eastern Time

March 23, 2026 09:00 ET  | Source: SKYX Platforms Corp.

MIAMI, March 23, 2026 (GLOBE NEWSWIRE) — SKYX Platforms Corp. (NASDAQ: SKYX) (d/b/a SKYX Technologies) (the “Company” or “SKYX”), a highly disruptive smart home platform technology company with over 100 pending and issued patents globally and 60 lighting and home décor websites, with a mission to make homes and buildings become safe and smart as the new standard, announces today that it will host a Corporate Update call and present fourth quarter 2025 and 2025 full year overview and financial results. The conference call will be held on Thursday, March 26, 2026, at 4:30 p.m. Eastern Time.

SKYX Participating Members will Include:

  • Rani Kohen, Founder and Executive Chairman
  • Lenny Sokolow, CEO
  • Steve Schmidt, SKYX President, (Former CEO of Nielsen Data Corporation and former President of Office Depot International)
  • Marc Boisseau, CFO

SKYX Platforms – Q4 2025 and 2025 Full Year Corporate Update Call

Date: Thursday, March 26, 2026
Time: 4:30 p.m. Eastern Time
U.S./Canada Dial-in: 1-412-317-5180
International Dial-in: 1-844-825-9789 

Call me™ link for instant telephone access to the event: https://callme.viavid.com/?$Y2FsbG1lPXRydWUmcGFzc2NvZGU9JmluZm89Y29tcGFueSZyPXRydWUmYj0xNg==

Call me™ Passcode: 8524520

Webcast link: https://viavid.webcasts.com/starthere.jsp?ei=1757430&tp_key=97c42ef65d

Please dial in at least 10 minutes before the start of the call to ensure timely participation.
A playback of the call will be available until April 26, 2026. To listen, call within the United States and Canada or when calling internationally. Please use the replay pin number 10207623. A webcast is also available at the following link:
https://viavid.webcasts.com/starthere.jsp?ei=1757430&tp_key=97c42ef65d

About SKYX Platforms Corp.

As electricity is a standard in every home and building, our mission is to make homes and buildings become safe-advanced and smart as the new standard. SKYX has a series of highly disruptive advanced-safe-smart platform technologies, with over 100 U.S. and global patents and patent pending applications. Additionally, the Company owns 60 lighting and home decor websites for both retail and commercial segments. Our technologies place an emphasis on high quality and ease of use, while significantly enhancing both safety and lifestyle in homes and buildings. We believe that our products are a necessity in every room in both homes and other buildings in the U.S. and globally. For more information, please visit our website at https://skyplug.com/ or follow us on LinkedIn.

Forward-Looking Statements

Certain statements made in this press release are not based on historical facts but are forward-looking statements. These statements can be identified by the use of forward-looking terminology such as “aim,” “anticipate,” “believe,” “can,” “could,” “continue,” “estimate,” “expect,” “evaluate,” “forecast,” “guidance,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “outlook,” “plan,” “potential,” “predict,” “probable,” “project,” “seek,” “should,” “target” “view,” “will,” or “would,” or the negative thereof or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. These statements reflect the Company’s reasonable judgment with respect to future events and are subject to risks, uncertainties and other factors, many of which have outcomes difficult to predict and may be outside our control, that could cause actual results or outcomes to differ materially from those in the forward-looking statements. Such risks and uncertainties include statements relating to the Company’s ability to successfully launch, commercialize, develop additional features and achieve market acceptance of its products and technologies and integrate its products and technologies with third-party platforms or technologies; the Company’s efforts and ability to drive the adoption of its products and technologies as a standard feature, including their use in homes, hotels, offices and cruise ships; the Company’s ability to capture market share; the Company’s estimates of its potential addressable market and demand for its products and technologies; the Company’s ability to raise additional capital to support its operations as needed, which may not be available on acceptable terms or at all; the Company’s ability to continue as a going concern; the Company’s ability to execute on any sales and licensing or other strategic opportunities; the possibility that any of the Company’s products will become National Electrical Code (NEC)-code or otherwise code mandatory in any jurisdiction, or that any of the Company’s current or future products or technologies will be adopted by any state, country, or municipality, within any specific timeframe or at all; risks arising from mergers, acquisitions, joint ventures and other collaborations; the Company’s ability to attract and retain key executives and qualified personnel; guidance provided by management, which may differ from the Company’s actual operating results; the potential impact of unstable market and economic conditions on the Company’s business, financial condition, and stock price; and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including its periodic reports on Form 10-K and Form 10-Q. There can be no assurance as to any of the foregoing matters. Any forward-looking statement speaks only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by U.S. federal securities laws.

Investor Relations Contact:

Jeff Ramson
PCG Advisory
[email protected]

Release – Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy

Posted on by [email protected]

Research News and Market Data on OCGN

March 23, 2026

PDF Version

MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast with key opinion leaders (KOLs) and Ocugen executive leadership to discuss the full data set from the Phase 2 ArMaDa clinical trial evaluating OCU410 for geographic atrophy (GA), late-stage dry age-related macular degeneration (dAMD) at 8 a.m. EDT on Tuesday, March 24, 2026.

KOLs leading the webcast include:

  • Lejla Vajzovic, MD, FASRS, Professor of Ophthalmology, Director of CME-Ophthalmology, Duke University School of Medicine & Chairman, Ocugen Scientific Advisory Board
  • Jay Chhablani, MD, Professor, University of Pittsburgh and UPMC Vision Institute, and President of NetraMind

Victor H. Gonzalez, MD, Retinal Surgeon, Valley Retina Institute, McAllen, Texas, Faculty at University of Texas Rio Grande Valley; and Syed M. Shah, MD, Vice Chair for Research and Digital Medicine, Director of Retina Service, Department of Ophthalmology at Emplfiy Health, La Crosse, WI, Ibn al-Haytham Professor, Department of Ophthalmology, Aga Khan University will join to answer questions.

Attendees are invited to participate on the call using the following details:

Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callers
Conference ID: 4629682
Webcast: Available on the events section of the Ocugen investor site

A replay of the call and archived webcast will be available following the event on the Ocugen investor site.

About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:
Tiffany Hamilton
AVP, Head of Communications
[email protected]

Eledon Pharmaceuticals (ELDN) – FY2025 Reported With Tegoprubart Updates and Phase 3 Expectations

Posted on by [email protected]


Monday, March 23, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Tegoprubart Trials To Advance In FY2026. Eledon reported a 4Q loss of $10.4 million or $(0.11) per share and a FY2025 loss of $45.6 million or $(0.52) per share. The FY Total Operating Expenses were $83.3 million, with non-cash items (including changes in the fair value of warrant liabilities) of $33.4 million. Net Loss excluding these items would have been $79.1 million for full year. Updates for tegoprubart clinical development were also confirmed with the announcement. Cash on December 31, 2025 was $45.6 million.

Clinical Trials In Transplantation Have Several Milestones Ahead. Eledon expects to meet with the FDA to discuss plans for a Phase 3 tegoprubart trial for prevention of kidney transplant rejection. We expect the guidance to clarify required endpoints and could lead to the start of Phase 3 by year-end. Guidance is also expected for Islet cell transplantation in diabetes and xenotransplantation.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Titan International (TWI) – Production Consolidation

Posted on by [email protected]


Monday, March 23, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Consolidation. Last week, Titan announced a decision to consolidate production within its North American manufacturing footprint, which will result in the closure of its manufacturing facility in Jackson, Tennessee, by the end of October 2026. The Company expects production currently performed in Jackson to be transitioned to other existing Titan facilities over the coming months. We view this action as part of the Company’s ongoing efforts to optimize its manufacturing footprint and improve capacity utilization, given the uncertain operating environment.

Details. The Jackson closure is part of the ongoing synergies the Company expected to deliver from the Carlstar acquisition. The one-time costs for the plant closure and manufacturing relocation are estimated to be in the $7 million range, likely to hit in relatively equal amounts over the next three quarters. Estimated annual savings are in the $5 million range, with the full amount likely to begin in 2027.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

1-800-Flowers.com (FLWS) – Raising Rating: Unleashing AI To Drive Efficiency And Growth

Posted on by [email protected]


Monday, March 23, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Highlights from a fireside chat. This report highlights a fireside chat with Adolfo Villagomez, CEO, who discussed the company’s four pillar initiative to transform the company into a more efficient, growth focused company. 

Improving the company’s cost structure. Management has implemented a comprehensive review of the organization’s operations with the goal of reducing redundancies and improving productivity. The company is targeting approximately $50 million in run-rate cost savings across fiscal years 2026 and 2027, achieved through initiatives such as workforce streamlining, supply chain optimization, procurement improvements, and the reduction of organizational layers.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – Snail Games Leverages GDC 2026 Momentum to Drive Portfolio Growth Through Steam Spring Sale 2026 Featuring ARK: Survival Ascended, Echoes of Elysium, and Bellwright

Posted on by [email protected]

Research News and Market Data on SNAL

March 20, 2026 at 8:30 AM EDT

PDF Version

CULVER CITY, Calif., March 20, 2026 (GLOBE NEWSWIRE) — Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, returned from an impactful showing at GDC 2026, where the Company unveiled major content updates to the ARK franchise, announced a new Wandering Wizard indie title Gobby Gang, and highlighted key milestones achieved across its current portfolio, including reaching the 1-million-unit-sold benchmark for Bellwright and increasing Echoes of Elysium’s positive rating by over 50% within 3 months of Early Access launch. Building on the excitement generated at GDC, Snail Games is bringing that momentum directly to players by featuring ARK titles, Bellwright, Echoes of Elysium, among others in the Steam Spring Sale.

As part of the Steam Spring Sale, Snail Games is offering discounts across a selection of its standout titles, including ARK: Survival Ascended (75% off), PixARK (57% off), Bellwright (34% off), Echoes of Elysium (20% off) and many more. The promotion provides players with an opportunity to engage with both newly showcased experiences and proven fan-favorites, expanding access to the Company’s diverse lineup while capitalizing on increased seasonal traffic across the Steam platform.

Seasonal sales remain a critical driver of visibility and unit growth, particularly when paired with the heightened awareness generated by industry events like GDC. By aligning its promotional strategy with key market moments, Snail Games aims to amplify discovery, convert interest into sales, and reinforce the long-term value of its IP portfolio among both new and returning players.

For creators interested in collaborating with any Snail Games’ titles please reach out to [email protected]

About Snail, Inc.
Snail, Inc. (Nasdaq: SNAL) is a leading, global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs, and mobile devices. For more information, please visit: https://snail.com/

Forward-Looking Statements
This press release contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this press release can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “may,” “predict,” “continue,” “estimate” and “potential,” or the negative of these terms or other similar expressions. Forward-looking statements appear in a number of places in this press release and include, but are not limited to, statements regarding Snail leveraging GDC 2026 momentum to drive portfolio growth through Steam Spring Sale 2026 Featuring ARK: Survival Ascended, Echoes of Elysium, and Bellwright; Snail Games aiming to amplify discovery, convert interest into sales, and reinforce the long-term value of its IP portfolio among both new and returning players by aligning its promotional strategy with key market moments, and assumptions underlying any of the foregoing.

Further information on risks, uncertainties and other factors that could affect Snail’s financial results and business include Snail’s ability to continue the momentum to drive portfolio growth; its ability to amplify discovery, convert interest into sales, and reinforce the long-term value of its IP portfolio ; and the risks that are included in its filings with the Securities and Exchange Commission (the “SEC”) from time to time, including its annual reports on Form 10-K and quarterly reports on Form 10-Q filed, or to be filed, with the SEC. You should not rely on these forward-looking statements, as actual outcomes and results may differ materially from those expressed or implied in the forward-looking statements as a result of such risks and uncertainties. All forward-looking statements in this press release are based on management’s beliefs and assumptions and on information currently available to Snail, and Snail does not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact:
John Yi and Steven Shinmachi
Gateway Group, Inc.
949-574-3860
[email protected]